FDA authorizes adolescent use of Omicron-specific boosters
Bivalent booster shots specific to currently circulating Omicron strains will soon be available to children as young as 5 years old.
The FDA has authorized Pfizer and BioNTech’s booster in children ages 5 through 11, the companies announced on Wednesday, as well as Moderna’s formulation in kids 6 through 17 years old. Both shots are specific to the Omicron BA.4/BA.5 subvariants, which account for more than 80% of cases in the US, according to Pfizer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.